🔎 Trials Near Me

Akèy › Limfom zòn marenal

Etid klinik pou Limfom zòn marenal ap rekrite nan Etazini

55 etid pou Limfom zòn marenal ap rekrite patisipan nan sit atravè Etazini.

Vil ki gen plis etid

Pa eta

Etid ki fèk mete ajou

Tèks ofisyèl etid la (Anglè)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06350318

Epco, Zanu, Ritux for R/R FL or MZL

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06563596

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05296070

A Study of ARC-02 in B-cell NHL

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04792502

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06792825

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Ap rekriteFaz 1
Laj 18 a 81 · Tout sèks · Mizajou Aug 6, 2026 · NCT05990465

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06708897

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946

Allo HSCT Using RIC and PTCy for Hematological Diseases

Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06860880

Registry of Older Patients With Cancer

Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.